Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options

SIMPLE SUMMARY: Pancreatic neuroendocrine neoplasms (PNENs) are a type of pancreatic tumor. Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR). Although PNENs respond well to systematic treatment, including everolimus, the treatment options are often exhausted in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurita, Yusuke, Kobayashi, Noritoshi, Hara, Kazuo, Mizuno, Nobumasa, Kuwahara, Takamichi, Okuno, Nozomi, Haba, Shin, Tokuhisa, Motohiko, Hasegawa, Sho, Kubota, Kensuke, Nakajima, Atsushi, Ichikawa, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688517/
https://www.ncbi.nlm.nih.gov/pubmed/36428761
http://dx.doi.org/10.3390/cancers14225669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688517/
https://www.ncbi.nlm.nih.gov/pubmed/36428761
http://dx.doi.org/10.3390/cancers14225669

Ejemplares similares